Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Johnson & Johnson 2014 Johnson & Johnson Annual Report. Available at:
http://files.shareholder.com/downloads/JNJ/194526085x0x815170/816798CD-60D9-4653-BB5A-50A66FD5B9E7/JNJ_2014_Annual_Report_bookmarked_.pdf
(accessed on 25 February 2016).
2. Lauffenburger J, Farley J, Gehi A, Rhoney D, Brookhart M, Fang G . Factors driving anticoagulant selection in patients with atrial fibrillation in the united states. Am J Cardiol 2015; 115 (8): 1095–1101.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10): 883–891.
4. Wadhera RK, Russell CE, Piazza G . Warfarin versus novel oral anticoagulants: how to choose? Circulation 2014; 130 (22): e191–e193.
5. Madan S, Shah S, Partovi S, Parikh SA . Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther 2014; 4 (4): 314–323.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献